An international agreement that may reach $1.4 billion in value may disrupt the COVID-19 and influenza vaccine industry.
As part of Sanofi's commitment to developing a diverse portfolio of best-in-class vaccines, the company announced today it has entered into a co-exclusive licensing agreement with Novavax Inc., a global leader in protein-based, non-mRNA, adjuvanted COVID-19 vaccines.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
